Your browser is no longer supported. Please, upgrade your browser.
Settings
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E42.07 EPS (ttm)0.41 Insider Own3.30% Shs Outstand148.20M Perf Week-1.09%
Market Cap2.56B Forward P/E- EPS next Y-0.68 Insider Trans-19.44% Shs Float124.89M Perf Month-0.12%
Income68.40M PEG0.76 EPS next Q-0.23 Inst Own92.10% Short Float6.78% Perf Quarter-13.19%
Sales317.90M P/S8.04 EPS this Y156.20% Inst Trans1.30% Short Ratio10.93 Perf Half Y-3.31%
Book/sh1.78 P/B9.69 EPS next Y18.50% ROA- Target Price20.63 Perf Year44.96%
Cash/sh2.69 P/C6.41 EPS next 5Y55.00% ROE- 52W Range11.41 - 21.48 Perf YTD-14.86%
Dividend- P/FCF19.63 EPS past 5Y24.10% ROI20.10% 52W High-19.69% Beta1.95
Dividend %- Quick Ratio3.40 Sales past 5Y49.50% Gross Margin91.60% 52W Low51.18% ATR0.54
Employees255 Current Ratio3.50 Sales Q/Q4.10% Oper. Margin28.40% RSI (14)45.08 Volatility2.67% 3.34%
OptionableYes Debt/Eq0.65 EPS Q/Q- Profit Margin- Rel Volume0.80 Prev Close16.99
ShortableYes LT Debt/Eq0.31 EarningsAug 07 AMC Payout- Avg Volume774.56K Price17.25
Recom2.70 SMA20-1.43% SMA50-3.35% SMA200-8.17% Volume832,551 Change1.53%
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Jun-12-14Upgrade UBS Neutral → Buy $14 → $16
Jan-10-14Reiterated Barclays Equal Weight $12 → $15
Nov-11-13Reiterated UBS Neutral $8 → $14
Nov-11-13Reiterated Barclays Equal Weight $8 → $12
Aug-02-13Downgrade Barclays Overweight → Equal Weight $9 → $8
May-01-13Reiterated UBS Neutral $8 → $6.50
Sep-24-12Reiterated Barclays Overweight $8 → $10
Aug-08-18 07:30AM  Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:05AM  Halozyme Therapeutics: 2Q Earnings Snapshot Associated Press
Aug-07-18 04:21PM  Halozyme Reports Second Quarter 2018 Results PR Newswire
02:30PM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Repligen ACCESSWIRE
Jul-26-18 04:15PM  Halozyme Therapeutics To Participate In Upcoming Healthcare Conference PR Newswire
08:00AM  Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology PR Newswire
Jul-11-18 08:30AM  FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin PR Newswire
Jul-06-18 08:00AM  Halozyme To Host Second Quarter 2018 Financial Results Conference Call PR Newswire
Jun-26-18 03:38PM  How Did Halozyme Therapeutics Incs (NASDAQ:HALO) 25.81% ROE Fare Against The Industry? Simply Wall St.
Jun-22-18 07:30AM  Free Technical Research on ImmunoGen and Three More Biotech Equities ACCESSWIRE
Jun-13-18 08:00AM  Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-11-18 08:30AM  Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego PR Newswire
Jun-01-18 08:30AM  Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer PR Newswire
May-29-18 04:15PM  Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences PR Newswire
May-24-18 03:00AM  Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
May-15-18 08:00AM  Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics ACCESSWIRE
May-11-18 03:46AM  Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents -5.73%
May-10-18 04:44PM  Halozyme Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Halozyme Reports First Quarter 2018 Results PR Newswire
Apr-10-18 08:00AM  Halozyme To Host First Quarter 2018 Financial Results Conference Call PR Newswire
Mar-22-18 05:46PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc. Business Wire
04:05PM  Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting PR Newswire
Mar-14-18 04:37PM  Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference PR Newswire
Mar-01-18 04:26PM  Edited Transcript of HALO earnings conference call or presentation 20-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-18 08:00AM  Halozyme Therapeutics To Present At Upcoming Healthcare Conference PR Newswire
Feb-23-18 07:45AM  New Research: Key Drivers of Growth for Trinseo S.A, Camden Property Trust, Lions Gate Entertainment, Aramark, J.M. Smucker, and Halozyme Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-22-18 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
Feb-20-18 04:49PM  Halozyme Therapeutics tops Street 4Q forecasts Associated Press
04:05PM  Halozyme Reports Fourth Quarter And Full-Year 2017 Results PR Newswire
12:00PM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 09:00AM  Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock Zacks
Feb-09-18 10:22AM  Halozyme Therapeutics Inc (NASDAQ:HALO): Should The Recent Earnings Drop Worry You? Simply Wall St.
Feb-05-18 05:43PM  First Eagle Reduces Halozyme Therapeutics Stake GuruFocus.com
Feb-02-18 07:14PM  Cramer's lightning round: Shopify's doing well, but you s... CNBC Videos
Jan-29-18 05:39PM  First Eagle Fund of America 4th Quarter Commentary GuruFocus.com
Jan-25-18 08:10AM  Todays Research Reports on Stocks to Watch: Cerus Corporation and Halozyme Therapeutics ACCESSWIRE
Jan-22-18 08:00AM  Halozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call PR Newswire +5.39%
Jan-19-18 02:46PM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO) Business Wire
Jan-17-18 02:50PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) PR Newswire -8.92%
01:48PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO PR Newswire
12:05PM  This News Explains Halozyme Therapeutics' Double-Digit Drop Today Motley Fool
Jan-11-18 03:00AM  Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92 Investor's Business Daily
Jan-09-18 06:30PM  Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 PR Newswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Jan-01-18 09:18AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-27-17 08:00AM  Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-26-17 10:30AM  3 Top Stocks Wall Street Is Overlooking Motley Fool
Dec-19-17 01:11PM  ETFs with exposure to Halozyme Therapeutics, Inc. : December 19, 2017 Capital Cube
Dec-18-17 07:14PM  Cramer's lightning round: Roku's one of the most amazing ... CNBC Videos
Dec-15-17 09:12AM  The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals Zacks
08:55AM  Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge Zacks
Dec-11-17 09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:35AM  Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock Zacks
Dec-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation ACCESSWIRE
Dec-07-17 09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers TheStreet.com
06:30AM  Alexion and Halozyme Enter License Agreement for ENHANZE Technology Business Wire
Nov-30-17 08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-28-17 08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-27-17 08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-24-17 08:07AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-22-17 09:15PM  Barron's After Hours: Halozyme Jumps, WPX Energy Slumps, Delphi Technologies Falls Barrons.com -5.00%
Nov-21-17 08:00AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Acorda Therapeutics ACCESSWIRE
Nov-20-17 08:49AM  Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options Zacks
Nov-15-17 09:13PM  Edited Transcript of HALO earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
08:00AM  Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences PR Newswire
Nov-14-17 02:55PM  CORRECTING and REPLACING Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-13-17 07:50AM  Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-10-17 08:30AM  Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors PR Newswire
08:07AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Nov-08-17 07:04PM  Cramer's lightning round: Step aside, Exxon. Cimarex's mo... CNBC Videos +13.36%
02:19PM  Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High Motley Fool
Nov-07-17 06:01PM  Halozyme Therapeutics beats 3Q profit forecasts Associated Press
04:05PM  Halozyme Reports Third Quarter 2017 Results PR Newswire
10:10AM  Halozyme Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-03-17 08:44AM  Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings? Zacks
08:06AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Oct-31-17 08:30AM  Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology PR Newswire
08:00AM  Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Teva Pharmaceuticals ACCESSWIRE
Oct-30-17 11:55AM  ETFs with exposure to Halozyme Therapeutics, Inc. : October 30, 2017 Capital Cube
Oct-25-17 08:08AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Oct-24-17 08:30AM  First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy PR Newswire
Oct-18-17 09:47AM  ETFs with exposure to Halozyme Therapeutics, Inc. : October 18, 2017 Capital Cube
Oct-17-17 08:06AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
07:32AM  3 Drug Stocks Hitting 52-Week Highs: Are They Buys? Motley Fool
Oct-16-17 09:46AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
08:00AM  Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients PR Newswire
Oct-13-17 08:00AM  Todays Research Reports on Trending Tickers: Halozyme Therapeutics and Akers Biosciences ACCESSWIRE
Oct-10-17 08:00AM  Halozyme to Host Third Quarter 2017 Financial Results Conference Call PR Newswire
06:03AM  3 Monster Stocks in the Making Motley Fool
Oct-06-17 10:53AM  ETFs with exposure to Halozyme Therapeutics, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:34AM  Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Oct-02-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Sep-29-17 11:34AM  1 Great Biotech Stock You Have Never Heard Of Motley Fool
Sep-28-17 08:05AM  See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc. Markit
Sep-22-17 08:35AM  Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions? Zacks
Sep-20-17 08:45AM  Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook Zacks
Sep-16-17 10:47AM  Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? Motley Fool
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRK RANDAL J10% OwnerAug 10Sale17.08202,9593,466,5403,276,273Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 09Sale17.48223,1273,900,2603,396,879Aug 10 05:00 PM
KIRK RANDAL J10% OwnerAug 08Sale17.52146,7182,570,4993,529,470Aug 10 05:00 PM
KIRK RANDAL J10% OwnerJul 27Sale16.9048,927826,8663,616,655Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 26Sale17.30150,0002,595,0003,645,729Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJul 25Sale17.32103,9001,799,5483,734,865Jul 27 04:35 PM
KIRK RANDAL J10% OwnerJun 29Sale16.97122,4312,077,6543,796,606Jun 29 09:55 PM
KIRK RANDAL J10% OwnerJun 28Sale16.99128,3852,181,2613,869,359Jun 29 09:55 PM
KIRK RANDAL J10% OwnerJun 27Sale17.3453,505927,7773,945,650Jun 29 09:55 PM
Stelzer LaurieSVP, Chief Financial OfficerJun 15Option Exercise0.006,875054,385Jun 18 04:23 PM
Chondros DimitriosSVP, Chief Medical OfficerJun 01Option Exercise0.002,043036,119Jun 05 04:06 PM
LEONHARDT HARRY JSVP, GC and CCOApr 13Option Exercise0.006,875041,935Apr 13 07:15 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 22Option Exercise0.0011,392038,999Feb 23 05:14 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540348,997Feb 23 05:09 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,392051,449Feb 23 05:13 PM
Torley HelenPresident and CEOFeb 06Option Exercise0.0031,2500325,136Feb 06 07:43 PM
LEONHARDT HARRY JSVP, GC and CCOFeb 03Option Exercise0.0015,413033,212Feb 05 04:27 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,120048,322Feb 05 04:25 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870317,997Feb 05 04:22 PM
Torley HelenPresident and CEOJan 06Option Exercise0.0030,0000274,159Jan 09 06:35 PM